ETPrime

Suven Pharma - Cohance Lifesciences Share Price

  • 1,012.9590.06 (9.76%)
  • Volume: 49,38,667
  • Closed
  • Last Updated On: 08 Sep, 2025, 03:49 PM IST
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Suven Pharma - Cohance Lifesciences Share Price
  • 1,012.9590.06 (9.76%)
  • Volume: 49,38,667
Advertisment
Stock Recommendations

  • Potential
    Upside

  • 1 Year
    Target

STRONG BUY

Mean Recos by
6 Analysts

0

0

0

3

3

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Suven Pharma share price insights

View All

  • Company witnessed QoQ revenue growth of 36.57%, which is highest in the last 3 years. (Source: Consolidated Financials)

  • 50 day moving crossover appeared yesterday. Average price gain of 5.15% within 30 days of this signal in last 5 years.

  • Company's annual revenue growth of 12.83% outperformed its 3 year CAGR of -3.8%. (Source: Consolidated Financials)

  • Weekly stochastic crossover appeared on week ending Sep 05, 2025. Average price gain of 8.08% within 7 weeks of this signal in last 10 years.

  • Cohance Lifesciences Ltd. share price moved up by 9.76% from its previous close of Rs 922.90. Cohance Lifesciences Ltd. stock last traded price is 1,012.95

    Share PriceValue
    Today/Current/Last1,012.95
    Previous Day922.90923.10

InsightsSuven Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		151.39
    EPS - TTM
    (₹)    		6.69
    MCap
    (₹ Cr.)    		38,752.14
    Sectoral MCap Rank
    		16
    PB Ratio
    (x)    		19.18
    Div Yield
    (%)    		0.00
    Face Value
    (₹)    		1.00
    Beta

    Beta

    1 Month-
    3 Months-
    6 Months-
    1 Year-
    3 Years-

    		-
    VWAP
    (₹)    		977.05
    52W H/L
    (₹)
    1,360.00 / 856.30

    Suven Pharma Share Price Returns

    1 Day9.76%
    1 Week12.65%
    1 Month8.56%
    3 Months-3.99%
    1 Year-15.6%
    3 Years106.07%
    5 Years200.89%

    ET Stock ScreenersTop Score Companies

    Check whether Suven Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Suven Pharma News & Analysis

    View all Suven Pharma Share News & Announcements

    Suven Pharma Share Recommendations

    Recent Recos

    STRONG BUY

    Current

    Mean Recos by 6 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹1400
    • OrganizationICICI Securities
    • BUY
    • Target₹602
    • OrganizationGeojit Financial Services
    • ACCUMULATE

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy3333
    Buy3333
    Hold----
    Sell----
    Strong Sell----
    # Analysts6666
    View all Stock Recommendations

    Suven Pharma Financials

    • Insights

      • Quarterly Topline Performance

        Company witnessed QoQ revenue growth of 36.57%, which is highest in the last 3 years. (Source: Consolidated Financials)

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 12.83% outperformed its 3 year CAGR of -3.8%. (Source: Consolidated Financials)
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income563.48412.59322.86271.84248.85
      Total Income Growth (%)36.5727.7918.779.24-7.83
      Total Expenses490.54355.24209.80170.67164.16
      Total Expenses Growth (%)38.0969.3222.933.97-16.60
      EBIT72.9457.35113.06101.1784.69
      EBIT Growth (%)27.18-49.2711.7519.4615.77
      Profit after Tax (PAT)48.8842.0182.8882.2160.77
      PAT Growth (%)16.35-49.310.8135.2813.86
      EBIT Margin (%)12.9413.9035.0237.2234.03
      Net Profit Margin (%)8.6710.1825.6730.2424.42
      Basic EPS (₹)1.281.653.263.232.39
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income496.68336.80290.57249.49240.04
      Total Income Growth (%)47.4715.9116.473.94-7.81
      Total Expenses418.84278.18173.37147.34151.04
      Total Expenses Growth (%)50.5660.4517.67-2.45-19.25
      EBIT77.8458.62117.20102.1589.00
      EBIT Growth (%)32.79-49.9814.7314.7821.35
      Profit after Tax (PAT)52.5744.3486.3576.3365.08
      PAT Growth (%)18.56-48.6513.1317.2921.80
      EBIT Margin (%)15.6717.4040.3340.9437.08
      Net Profit Margin (%)10.5813.1729.7230.5927.11
      Basic EPS (₹)1.381.743.393.002.56
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue1,256.141,113.261,386.691,412.601,023.96
      Total Revenue Growth (%)12.83-19.72-1.8337.9620.20
      Total Expenses912.22707.59826.96786.12610.02
      Total Expenses Growth (%)28.92-14.445.1928.8723.08
      Profit after Tax (PAT)267.87300.28411.29453.80362.34
      PAT Growth (%)-10.79-26.99-9.3725.2414.30
      Operating Profit Margin (%)29.7439.2942.1647.9241.90
      Net Profit Margin (%)22.3628.5630.6834.3735.88
      Basic EPS (₹)10.5211.8016.1617.8314.23
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue1,147.491,080.091,374.631,508.011,023.96
      Total Revenue Growth (%)6.24-21.43-8.8447.2720.20
      Total Expenses796.14671.31795.24785.56609.98
      Total Expenses Growth (%)18.59-15.581.2328.7923.40
      Profit after Tax (PAT)271.71304.82432.60558.10308.65
      PAT Growth (%)-10.86-29.54-22.4980.8214.28
      Operating Profit Margin (%)32.8640.6043.9655.1941.90
      Net Profit Margin (%)24.8429.7332.5242.2730.56
      Basic EPS (₹)10.6711.9716.9921.9212.12

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets3,031.752,254.091,965.741,829.591,474.47
      Total Assets Growth (%)34.5014.677.4424.0825.72
      Total Liabilities1,191.11203.42230.56302.41293.66
      Total Liabilities Growth (%)485.53-11.77-23.762.98-10.48
      Total Equity1,840.642,050.661,735.181,527.181,180.81
      Total Equity Growth (%)-10.2418.1813.6229.3339.78
      Current Ratio (x)2.4311.826.375.362.57
      Total Debt to Equity (x)0.050.020.040.060.12
      Contingent Liabilities0.0056.3040.4329.3847.70
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets2,587.812,240.721,958.331,804.891,358.83
      Total Assets Growth (%)15.4914.428.5032.8322.32
      Total Liabilities272.26184.82208.95284.19293.64
      Total Liabilities Growth (%)47.31-11.55-26.48-3.22-10.49
      Total Equity2,315.552,055.901,749.381,520.691,065.18
      Total Equity Growth (%)12.6317.5215.0442.7636.07
      Current Ratio (x)3.3211.476.195.312.57
      Total Debt to Equity (x)0.030.020.040.060.13
      Contingent Liabilities0.0056.30190.8429.3847.70

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Decrease in Cash from Investing

        Company has used Rs 255.3 cr for investing activities which is an YoY decrease of 29.52%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities288.16358.48450.91330.00383.44
      Net Cash used in Investing Activities-255.30-362.25-194.84-136.21-311.40
      Net Cash flow from Financing Activities3.32-13.80-235.83-156.41-76.55
      Net Cash Flow38.17-17.5720.2437.38-4.51
      Closing Cash & Cash Equivalent85.4047.2364.8044.567.18
      Closing Cash & Cash Equivalent Growth (%)80.81-27.1245.42520.48-38.59
      Total Debt/ CFO (x)0.270.110.160.290.37
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities301.03370.65484.17269.89329.73
      Net Cash used in Investing Activities-320.94-381.58-235.57-90.36-257.66
      Net Cash flow from Financing Activities20.81-13.78-235.79-156.41-76.55
      Net Cash Flow0.90-24.7112.8123.12-4.48
      Closing Cash & Cash Equivalent19.3618.3143.0230.217.09
      Closing Cash & Cash Equivalent Growth (%)5.71-57.4342.41325.85952.86
      Total Debt/ CFO (x)0.230.100.140.350.43

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)15.7814.6423.7029.7130.68
      Return on Capital Employed (%)13.3619.2431.2739.0733.71
      Return on Assets (%)8.8313.3220.9224.8024.57
      Interest Coverage Ratio (x)35.1262.77112.74107.8249.73
      Asset Turnover Ratio (x)0.450.500.710.810.80
      Price to Earnings (x)111.1157.4729.3334.7234.84
      Price to Book (x)17.408.406.9310.3010.68
      EV/EBITDA (x)68.3836.8019.6423.4928.02
      EBITDA Margin (%)36.2144.4845.7250.8845.03
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)11.7314.8224.7236.7028.97
      Return on Capital Employed (%)15.1319.4932.4145.6537.14
      Return on Assets (%)10.4913.6022.0930.9222.71
      Interest Coverage Ratio (x)52.0762.61116.41123.2249.73
      Asset Turnover Ratio (x)0.450.490.710.830.82
      Price to Earnings (x)108.7056.8227.8628.2540.98
      Price to Book (x)12.758.386.8810.3411.84
      EV/EBITDA (x)71.0037.0819.2120.5728.02
      EBITDA Margin (%)38.0945.3647.1858.1545.03

    Financial InsightsSuven Pharma

    • Income (P&L)
    • Cash Flow

      • Quarterly Topline Performance

        Company witnessed QoQ revenue growth of 36.57%, which is highest in the last 3 years. (Source: Consolidated Financials)

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 12.83% outperformed its 3 year CAGR of -3.8%. (Source: Consolidated Financials)

      • Decrease in Cash from Investing

        Company has used Rs 255.3 cr for investing activities which is an YoY decrease of 29.52%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Suven Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Suven Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Suven Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Suven Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Suven Pharma Technicals

    • Bullish / Bearish signals for Suven Pharma basis selected technical indicators and moving average crossovers.

      50 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on: 8 Sep 2025

      50D EMA: 961.69

      Last 4 Buy Signals:15 Jul 2025
      Date30 days Gain/Loss %
      15 Jul 20256.10%
      5 May 20250.81%
      28 Apr 20251.50%
      11 Apr 20258.73%

      Average price gain of 5.15% within 30 days of Bullish signal in last 5 years

      Stochastic Crossover

      Bullish signal on weekly chart

      Appeared on: 5 Sep 2025

      Region: Oversold (Below 20)

      Last 4 Buy Signals:11 Jul 2025
      Date7 weeks Gain/Loss %
      11 Jul 202510.14%
      6 Jun 20250.61%
      25 Apr 20251.99%
      28 Mar 20250.37%

      Average price gain of 8.08% within 7 weeks of Bullish signal in last 10 years

      Show More
    • 47%
      Positive Movement since
      1st Jan 2005 on basis
      53%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic1063.151113.351238.00988.70938.50864.05739.40

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR47.7538.1437.16

    Suven Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Suven Pharma 151.3921.0515.7813.368.83-3.8029.7422.1010.522.430.050.27
          Laurus Labs94.9710.508.0111.823.834.2512.336.386.651.220.604.48
          Ipca Labs43.023.9910.6115.156.2715.1115.898.8035.142.630.190.99
          Ajanta Pharma34.808.5424.2830.1018.3511.0026.0219.8073.562.850.000.00
          Gland Pharma40.173.387.6311.436.227.9419.6612.4342.404.330.030.29
          Add More
          Annual Ratios (%)

          Choose from Peers

          • J B Chemicals
          • Piramal Pharma
          • Syngene Int.
          • Emcure Pharmaceuticals Ltd.
          • Wockhardt

          Choose from Stocks

            See All Parameters

          Peers InsightsSuven Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Suven Pharma Shareholding Pattern

            • Loading...
              Showing Suven Pharma Shareholding as on Jun 2025
              CategoryJun 2025Mar 2025Dec 2024Sep 2024
              Promoters66.4150.1050.1050.10
              Pledge0.000.000.000.00
              FII7.2311.0510.8410.70
              DII11.4016.5916.6716.95
              Mutual Funds8.9013.0413.1514.12
              Others14.9522.2522.3922.25
            • Showing Shareholding as on Jun 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters25,40,78,17066.41 %16.30
              Pledge00.00 %0.00
              FII2,76,44,9957.23 %-3.82
              DII4,36,18,21711.40 %-5.19
              MF3,40,48,2148.90 %-4.13
              Others5,72,25,75814.95 %-7.29

            Suven Pharma MF Ownership

            MF Ownership as on 31 July 2025

            View all Mutual Fund Schemes
            Top Searches:
            Suven Pharma News Suven Pharma Quarterly Results Suven Pharma Dividend Suven Pharma Q1 ResultsSuven Pharma Q2 ResultsSuven Pharma Q3 ResultsSuven Pharma Q4 Results

            Suven Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              Aug 13, 2025Jun 27, 2025Board MeetingQuarterly Results
              May 28, 2025Mar 26, 2025Board MeetingAudited Results
              Feb 12, 2025Dec 27, 2024Board MeetingQuarterly Results
              Dec 19, 2024Nov 21, 2024POM-
              Nov 28, 2024Oct 28, 2024COM-
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Special500%5.0Sep 09, 2022Aug 30, 2022
              Interim100%1.0Sep 09, 2022Aug 29, 2022
              Special100%1.0May 13, 2022May 03, 2022
              Interim100%1.0May 13, 2022May 02, 2022
              Special200%2.0Feb 15, 2022Feb 02, 2022
            • All TypesEx-DateRecord DateAnnounced onDetails
              BonusSep 25, 2020Sep 28, 2020Aug 17, 2020Bonus Ratio: 1 share(s) for every 1 shares held

            About Suven Pharma

            Cohance Lifesciences Ltd., incorporated in the year 2018, is a Small Cap company (having a market cap of Rs 38,752.14 Crore) operating in Pharmaceuticals sector. Cohance Lifesciences Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Duty Drawback and Other Operating Revenue for the year ending 31-Mar-2024. Show More

            • Executives

            • Auditors

            • AV

              Annaswamy Vaidheesh

              Executive Chairperson
              VP

              V Prasada Raju

              Managing Director
              SK

              Sudhir Kumar Singh

              Chief Executive Officer
              PP

              Pankaj Patwari

              Non Executive Director
              Show More
            • Karvy & Co.

            Industry

            Pharma - Indian

            Key Indices Listed on

            Nifty 500, BSE 500, Nifty MNC, + 18 more

            Address

            215 Atrium, C Wing, 8th Floor,819-821, Andheri Kurla Road, Chakala,Andheri East, Chakala MIDC,Mumbai, Maharashtra - 400093

            Contact

            info@suvenpharm.com

            www.suvenpharm.com

            More Details

            FAQs about Suven Pharma share

            • 1. What's Suven Pharma share price today and what are Suven Pharma share returns ?
              Suven Pharma share price is Rs 1,012.95 as on 08 Sep, 2025, 03:59 PM IST. Suven Pharma share price is up by 9.76% based on previous share price of Rs 899.3. Suven Pharma share price trend:
              • Last 3 Months: Suven Pharma share price moved down by 3.99%
              • Last 12 Months: Suven Pharma share price moved down 15.60%
              • Last 3 Years: Suven Pharma Share price moved up by 106.07%
            • 2. What are the returns for Suven Pharma share?
              Return Performance of Suven Pharma Shares:
              • 1 Week: Suven Pharma share price moved up by 12.65%
              • 3 Month: Suven Pharma share price moved down by 3.99%
              • 6 Month: Suven Pharma share price moved down by 13.13%
            • 3. What has been highest price of Suven Pharma share in last 52 weeks?
              52 Week high of Suven Pharma share is Rs 1,360.00 while 52 week low is Rs 856.30
            • 4. What's the market capitalization of Suven Pharma ?
              Within the Pharmaceuticals sector, Suven Pharma stock has a market cap rank of 16. Suven Pharma has a market cap of Rs 38,752.14 Cr.
            • 5. What is the PE & PB ratio of Suven Pharma ?
              The PE ratio of Suven Pharma stands at 137.93, while the PB ratio is 12.77.

            Trending in Markets

            Top Gainers As on 03:59 PM | 08 Sep 2025

            Suven Pharma 1,012.95
            90.06 (9.76%)
            Guj Mineral Dev.539.15
            30.15 (5.93%)
            Bharat Forge1,202.80
            66.10 (5.82%)
            Ashok Leyland137.29
            6.52 (4.99%)
            JP Power20.02
            0.95 (4.99%)

            Top Losers As on 03:57 PM | 08 Sep 2025

            Amber Enterprises7,473.00
            -320.50 (-4.12%)
            EID Parry1,067.30
            -45.50 (-4.09%)
            Trent5,315.50
            -213.00 (-3.86%)
            Godfrey Philips10,657.00
            -416.00 (-3.76%)
            Coromandel Int.2,185.20
            -72.71 (-3.22%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Suven Pharma Share Price
            The Economic Times
            BrowseCompanies: